Compare FedEx Corporation (FDX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Novo Nordisk A/S — how do they compare? FedEx Corporation trades at $291.66 (market cap $69.04B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.4× FedEx Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Novo Nordisk A/S for 116 Days on average.
| FDX | NVO | |
|---|---|---|
Market Cap | $69.04B | $165.31B |
Volume | 1,287,367 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $339.35 | $63.98 |
52-Week Low | $180.87 | $35.29 |
Typical Hold Time | 87 Days | 116 Days |
Enterprise Value | $98.68B | $179.56B |
Dividend Yield | 1.67% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.71, up 0.92% today, with a bearish technical signal but strong fundamentals including a P/E of 15.73 and net income margin of 4.68%. Recent Q1 2026 earnings beat expectations at $6.31 EPS. The company announced a $300 million electric truck order from Harbinger (TechCrunch, 2026-09-30) and a $1.22 dividend payable October 1, 2026. Cash flow from operations was $7.04B in 2025, with a projected rebound to $8.9B in 2026.
The outlook is mixed: analyst consensus is a Buy with a $307.55 price target, but rising fuel costs and geopolitical tensions pose margin risks. Earnings growth and cost-cutting initiatives support upside, while technical resistance near $294 may limit near-term gains. Debt-to-asset ratio is expected to rise to 25.99% in 2026, adding financial leverage concerns.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
